Frontline EGFR exon 20, adjuvant RET, and long-term ALK data are expected to sharpen biomarker-driven selection and potentially reset standards in defined molecular NSCLC subsets. PD-1/VEGF bispecific ...
No one fights alone”, that is the motto that I think of when I think of Jill Winther. Jill is a very experienced oncology ...
Oncology nurse Jill Winther was honored for decades of patient advocacy, education and compassionate support across cancer care settings.
Whether you are under 40 or over 80, breast cancer knows no age limits. Don’t stop getting mammograms just because “they” say ...
At ONS Congress 2026, Elianna Tobin shared how nurse navigator outreach helped patients feel more prepared before cancer ...
AI can augment oncology nursing through symptom triage support, trial matching, care plan personalization, pharmacogenomics ...
Learn the risk factors, symptoms and screening options tied to colorectal cancer as cases continue rising among younger ...
FDA approved adjuvant atezolizumab for post-cystectomy MIBC with ctDNA MRD positivity, alongside Signatera CDx as the required companion diagnostic for eligibility determination. IMvigor011 randomized ...
Some patients treated with immunotherapy may develop lifelong endocrine conditions requiring ongoing hormone replacement, ...
Neoadjuvant Enhertu→THP improved pCR to 67.3% vs 56.3% with AC→THP in stage II–III high-risk HER2-positive disease (DESTINY-Breast11). Adjuvant Enhertu achieved 3-year IDFS 92.4% vs 83.7% with T-DM1 ...
FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results